Mark J. Levis
Impact in
- Hematology top 0.02%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Oncology top 2%
Papers in
- Hematology 312
- Acute Myeloid Leukemia Research 293
- Hematopoietic Stem Cell Transplantation 19
- Chronic Myeloid Leukemia Treatments 3
-
- Acute Lymphoblastic Leukemia research 16
- Co-authors
- Bruce Douglas Smith (38 shared papers)Naval Guastad Daver (13 shared papers)Sabine Käyser (10 shared papers)Keith William Pratz (37 shared papers)Nigel H. Russell (11 shared papers)Alexander E. Perl (40 shared papers)Richard F. Schlenk (9 shared papers)Jörge E. Cortes (36 shared papers)
- Journals
- Blood (141 papers)Haematologica (22 papers)Blood Advances (20 papers)Leukemia (16 papers)Transplantation and Cellular Therapy (12 papers)
- Partner nations
- United StatesGermanyItaly
In The Last Decade
Mark J. Levis
333 papers receiving 20.9k citations
Mark J. Levis's Hit Papers
Peers
Comparison fields: 5 of 107
- Hematology 16.7k
- Oncology 1k
- Molecular Biology 2.2k
- Genetics 278
- Cancer Research 358
Countries citing papers authored by Mark J. Levis
This map shows the geographic impact of Mark J. Levis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Levis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Levis more than expected).
Fields of papers citing papers by Mark J. Levis
This network shows the impact of papers produced by Mark J. Levis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Levis. The network helps show where Mark J. Levis may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark J. Levis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 346 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML Hit paper breakdown → | 2019 | 994 |
| 2 | Targeting FLT3 mutations in AML: review of current knowledge and evidence Hit paper breakdown → | 2019 | 811 |
| 3 | Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia Hit paper breakdown → | 2012 | 638 |
| 4 | AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) Hit paper breakdown → | 2009 | 534 |
| 5 | Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia Hit paper breakdown → | 2004 | 533 |
| 6 | 2008 | 436 | |
| 7 | 2003 | 420 | |
| 8 | Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study Hit paper breakdown → | 2017 | 416 |
| 9 | 2002 | 398 | |
| 10 | Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial Hit paper breakdown → | 2019 | 387 |
| 11 | 2011 | 344 | |
| 12 | 2006 | 342 | |
| 13 | 2013 | 332 | |
| 14 | 2010 | 322 | |
| 15 | 2013 | 314 | |
| 16 | 1993 | 275 | |
| 17 | Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2023 | 268 |
| 18 | 2015 | 266 | |
| 19 | 2017 | 239 | |
| 20 | 2013 | 228 |
About Mark J. Levis
Mark J. Levis is a scholar working on Hematology, Public Health, Environmental and Occupational Health, Oncology, Molecular Biology and Emergency Medicine, having authored 346 papers that have together received 21.4k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (293 papers), Hematopoietic Stem Cell Transplantation (19 papers), Acute Lymphoblastic Leukemia research (16 papers), Retinoids in leukemia and cellular processes (10 papers), Chronic Myeloid Leukemia Treatments (3 papers), Hematological disorders and diagnostics (3 papers), PARP inhibition in cancer therapy (3 papers) and Digital Imaging for Blood Diseases (2 papers). The work is most often cited by research in Hematology (16.7k citations), Oncology (1k citations), Molecular Biology (2.2k citations), Genetics (278 citations) and Cancer Research (358 citations). Mark J. Levis has collaborated with scholars based in United States, Germany and Italy. Frequent co-authors include Bruce Douglas Smith, Naval Guastad Daver, Sabine Käyser, Keith William Pratz, Nigel H. Russell, Alexander E. Perl, Richard F. Schlenk, Jörge E. Cortes, Hagop M. Kantarjian and Trivikram Rajkhowa. Their work appears in journals such as Blood, Haematologica, Blood Advances, Leukemia and Transplantation and Cellular Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.